Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2019
Pharma News, 2019
EC extends license for Roche/Chugai’s Hemlibra
The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the d...
Servier & Oncodesign Partner for Parkinson's
Servier and Oncodesign have announced a strategic partnership for the research and development of potential drug candidates for Parkinson's disease.
National Cancer Chief, Ned Sharpless, Named F.D.A.’s Acting Commissioner
WASHINGTON — Dr.
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
DURHAM, N.
UK will be ‘less attractive’ for clinical research post Brexit
More than half (52%) of US biotech executives believe that the UK will be a ‘less attractive’ country for conducting clinical trials after Brexit, indicates new research by consultancy...
EMA now operating from Amsterdam Share
Amsterdam relocation As of today, EMA is operating from Amsterdam.
Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE.
FluroTech Advances Cannabis Biomarker Technology
SEATTLE, March 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American canna...
Lilly's combo therapy succeeds in late-stage lung cancer study
(Reuters) - Eli Lilly and Co’s combination cancer treatment met the main goal of a late-stage clinical trial testing it on patients with a form of lung cancer, the drugmaker announced on Tue...
French biotech Cellectis picks U.S. for commercial CAR-T production
Cellectis is building a 14,000-square-foot facility in Paris to produce clinical supplies, but the French biotech will also outfit a facility nearly six times that size in the U.
CORRECTING and REPLACING Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq.
Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinson’s Disease
NEW YORK and BASEL, Switzerland, March 11, 2019 (GLOBE NEWSWIRE) -- Axovant (Nasdaq.
45
46
47
48
49
50
51
52
53
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Inhibitors and Approved Drugs
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds
